Term
Humalog *RAPID ACTING*
(Lispro) |
|
Definition
Inject 5-15 min. before meal.
ONSET: 15-30 min.
PEAK: 1-2 hours
DURATION: 3-4 hours |
|
|
Term
Novolog *RAPID ACTING*
(Aspart) |
|
Definition
INJECT: 5-15min. before a meal
ONSET: 15-30 min.
PEAK: 1-3 hours
DURATION: 3-5 hours |
|
|
Term
Regular Insulin *SHORT ACTING*
(Humalin R)
(Novolin R) |
|
Definition
INJECT: 30 min before a meal (may be given IV)
ONSET: 30-60 min.
PEAK: 2-4 hours
DURATION: 6-8 hours |
|
|
Term
|
Definition
INJECT:30 min. before a meal.
ONSET: 2-4 hours
PEAK: 6-10 hours
DURATION: 12-16 hours |
|
|
Term
|
Definition
INJECT: 30 min before a meal.
ONSET: 1-3 hours
PEAK: 6-12 hours
DURATION: 18-26 hours |
|
|
Term
|
Definition
INJECT: Usually given once a day. Ultralente is cloudy.
ONSET: 3-5 hours
PEAK: 10-12 hours
DURATION: 36 hours |
|
|
Term
| Lantus *LONG ACTING*(Glargine) |
|
Definition
INJECT: Usually taken once a day @ 2100. DO NOT MIX WITH OTHER INSULIN. Acts as a basal insulin its clear but the bottle is distinctly different.
ONSET: 1-2 hours
PEAK: No pronounced peak
DURATION: 24 hours |
|
|
Term
Humalog 75/25 *RAPID/INTERMEDIATE*
25% INSULIN 75% LISPRO
LISPRO PROTAMINE |
|
Definition
Mix of rapid/intermediate
INJECT: 15 min before a meal offer when food is readily available
ONSET: 15-30 min.
PEAK: 2-10 hours
DURATION: 12-16 hours |
|
|
Term
NPH/Regular *SHORT/INTERMEDIATE*
MIX 70/30 Humalin 70/30 |
|
Definition
INJECT: 30-60 min. before a meal
ONSET: 30-60 min
PEAK: 6-12 hours
DURATION: 18-24 hours |
|
|
Term
Novolog 70/30 *RAPID/INTERMEDIATE*
Aspart/ generic Novolog/brand name
30% insulin aspart injection
70% insulin aspart protamine |
|
Definition
INJECT: 15 min before meal offer when food is readily available
ONSET: 15-30 min
PEAK: 2-10 hours
DURATION: 12-16 hours |
|
|
Term
* Alpha-Glucosidase *
Metabolized by intestinal bacteria and digestive enzymes; delay carbohydrate absorption from the small intestine |
|
Definition
*Acarbose (precose)
*Miglitol (glyset) |
|
|
Term
* Thiazolidinediones *
- Increases insulin sensitivity at insulin receptor sites on the cell. Thiazolidinediones are most appropriate for adults whose bodies produce insulin but cannot use it because of inadequate or ineffective insulin receptor sites |
|
Definition
*Rosiglitazone (Avandia) **Use with caution***
*Pioglitazone (Actos) |
|
|
Term
* Sulfonylureas *
-Insulin secretagogues primarily stimulate beta cells of the pancreas to release insulin, particullary in the early course of type 2 diabetes mellitus. Sulfonylureas increase the sensitivity to insulin at receptor sites. |
|
Definition
* Glipizide (glucotrol, glucotrol XL)
*GlyBURIDE (diaBeta, Micronase, Glynase)
*Glimepiride (Amaryl) |
|
|
Term
* Meglitinides *
Insulin secretagogues, like sulfonylureas, stimulate the beta cells in the pancreas to increase insulin release. Their effects, which are glucose dependant, decrease when the patients blood glucose level decreases. Requires functioning pancreatic beta cells. |
|
Definition
*Repaglinide (Prandin)
* Nateglinide (Starlix) |
|
|
Term
* Biguanide *
Works primarily by reducing hepatic glucose production and lowers fasting blood glucose levels. It also enhances tissue response to insulin and improves glucose transport to cells. |
|
Definition
| *Metformin (Glucophage, Glucophage XR, Fotamet, Riomet) |
|
|
